BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18544678)

  • 1. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.
    Rimsza LM; Leblanc ML; Unger JM; Miller TP; Grogan TM; Persky DO; Martel RR; Sabalos CM; Seligmann B; Braziel RM; Campo E; Rosenwald A; Connors JM; Sehn LH; Johnson N; Gascoyne RD
    Blood; 2008 Oct; 112(8):3425-33. PubMed ID: 18544678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
    Visco C; Li Y; Xu-Monette ZY; Miranda RN; Green TM; Li Y; Tzankov A; Wen W; Liu WM; Kahl BS; d'Amore ES; Montes-Moreno S; Dybkær K; Chiu A; Tam W; Orazi A; Zu Y; Bhagat G; Winter JN; Wang HY; O'Neill S; Dunphy CH; Hsi ED; Zhao XF; Go RS; Choi WW; Zhou F; Czader M; Tong J; Zhao X; van Krieken JH; Huang Q; Ai W; Etzell J; Ponzoni M; Ferreri AJ; Piris MA; Møller MB; Bueso-Ramos CE; Medeiros LJ; Wu L; Young KH
    Leukemia; 2012 Sep; 26(9):2103-13. PubMed ID: 22437443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Malumbres R; Chen J; Tibshirani R; Johnson NA; Sehn LH; Natkunam Y; Briones J; Advani R; Connors JM; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    Blood; 2008 Jun; 111(12):5509-14. PubMed ID: 18445689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
    Slack GW; Steidl C; Sehn LH; Gascoyne RD
    Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
    Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
    J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.
    Jais JP; Haioun C; Molina TJ; Rickman DS; de Reynies A; Berger F; Gisselbrecht C; Brière J; Reyes F; Gaulard P; Feugier P; Labouyrie E; Tilly H; Bastard C; Coiffier B; Salles G; Leroy K;
    Leukemia; 2008 Oct; 22(10):1917-24. PubMed ID: 18615101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
    Savage KJ; Johnson NA; Ben-Neriah S; Connors JM; Sehn LH; Farinha P; Horsman DE; Gascoyne RD
    Blood; 2009 Oct; 114(17):3533-7. PubMed ID: 19704118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
    Winter JN; Weller EA; Horning SJ; Krajewska M; Variakojis D; Habermann TM; Fisher RI; Kurtin PJ; Macon WR; Chhanabhai M; Felgar RE; Hsi ED; Medeiros LJ; Weick JK; Reed JC; Gascoyne RD
    Blood; 2006 Jun; 107(11):4207-13. PubMed ID: 16449523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
    Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD
    J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
    Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
    Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.
    Chaiwatanatorn K; Stamaratis G; Opeskin K; Firkin F; Nandurkar H
    Leuk Lymphoma; 2009 Oct; 50(10):1666-75. PubMed ID: 19757311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma.
    Roberts RA; Sabalos CM; LeBlanc ML; Martel RR; Frutiger YM; Unger JM; Botros IW; Rounseville MP; Seligmann BE; Miller TP; Grogan TM; Rimsza LM
    Lab Invest; 2007 Oct; 87(10):979-97. PubMed ID: 17700562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
    Mounier N; Briere J; Gisselbrecht C; Emile JF; Lederlin P; Sebban C; Berger F; Bosly A; Morel P; Tilly H; Bouabdallah R; Reyes F; Gaulard P; Coiffier B
    Blood; 2003 Jun; 101(11):4279-84. PubMed ID: 12576316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.